---
title: "Outlook Therapeutics (OTLK.US) — 财务报表"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/OTLK.US/norm.md"
symbol: "OTLK.US"
name: "Outlook Therapeutics"
parent: "https://longbridge.com/zh-CN/quote/OTLK.US.md"
datetime: "2026-06-14T02:39:51.857Z"
locales:
  - [en](https://longbridge.com/en/quote/OTLK.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OTLK.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OTLK.US/norm.md)
---

# Outlook Therapeutics (OTLK.US) — 财务报表

## 利润表 (USD)

| 指标 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
| --- | --- | --- | --- | --- | --- |
| 每股收益 | -0.0544 | -0.3830 | -0.2831 | -0.5500 | -1.50 |
| ROE | 52.74% | 260.78% | 153.28% | 231.46% | 448.15% |
| 营业收入 | 127439.00 | -1.21M | -91787.00 | 1.51M | - |
| 净利润 | -4.45M | -23.06M | -13.29M | -20.15M | -46.36M |
| 营业利润 | -14.03M | -13.48M | -17.31M | -15.75M | -12.39M |
| 毛利率 | -17.18% | 102.45% | -22000.47% | -403.18% | - |
| 净利率 | -3494.28% | 1909.05% | 14482.19% | -1338.75% | - |
| 利润含金量 | - | - | - | - | - |

## 资产负债表 (USD)

| 指标 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
| --- | --- | --- | --- | --- | --- |
| 资产与负债 | 21.89M | 18.24M | 18.58M | 22.39M | 19.08M |
| 权益乘数 | -0.7550 | -0.4731 | -0.5774 | -0.6021 | -0.5876 |
| 每股净资产 | -0.2772 | -0.5971 | -0.5973 | -0.8553 | -0.9865 |
| 资产周转率 | 0.0163 | 0.0117 | 0.0596 | 0.0433 | - |
| 现金及短投 | 7.75M | 8.68M | 8.08M | 8.90M | 7.56M |
| 存货与应收 | 3.34M | 3.46M | 3.34M | 4.13M | 3.60M |
| 长期投资 | 198975.00 | 212413.00 | 225508.00 | 238266.00 | 250699.00 |
| 净债务 | 19.44M | 28.22M | 22.11M | 25.80M | 25.76M |

## 现金流量表 (USD)

| 指标 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
| --- | --- | --- | --- | --- | --- |
| 经营现金流 | -7.83M | -14.94M | -12.38M | -11.90M | -16.58M |
| 投资现金流 | - | - | - | - | - |
| 融资现金流 | 6.90M | 15.53M | 11.56M | 13.25M | 18.44M |
| 自由现金流 | -2.00M | -10.17M | -7.71M | -5.42M | -10.97M |
| 现金流充裕率 | -46.05% | - | -532.22% | -1312.18% | -50.39% |
| 举债与偿债 | 17.00M | - | 0.0000 | 0.0000 | 33.10M |
| 资本支出 | - | - | - | - | - |